Showing results (371-380 of 447) with videos related to
Sort By:
Pageof 45
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2017
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled AnalysisSandra P D'Angelo, James Larkin, Jeffrey A Sosman, et al.Frontiers in Oncology|November 8, 2021
Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition - A Descriptive Observational Retrospective Multicenter AnalysisAnne Zaremba, Rafaela Kramer, Viola De Temple, et al.Nature Genetics|February 4, 2014
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencingMarco Gerlinger, Stuart Horswell, James Larkin, et al.European Journal of Cancer (Oxford, England : 1990)|March 22, 2015
Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanomaDirk Schadendorf, Mayur M Amonkar, Daniil Stroyakovskiy, et al.European Journal of Cancer (Oxford, England : 1990)|January 24, 2018
Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective studySara Valpione, Matteo S Carlino, Johanna Mangana, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 12, 2023
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401Reinhard Dummer, Pippa Corrie, Ralf Gutzmer, et al.Nature Cancer|June 26, 2023
Interferon signaling promotes tolerance to chromosomal instability during metastatic evolution in renal cancerLuigi Perelli, Federica Carbone, Li Zhang, et al.Annals of the Rheumatic Diseases|April 25, 2020
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitorsMarie Kostine, Axel Finckh, Clifton O Bingham, et al.Human Molecular Genetics|November 28, 2012
Common variation at 2q22.3 (ZEB2) influences the risk of renal cancerMarc Henrion, Matthew Frampton, Ghislaine Scelo, et al.Nature Medicine|September 8, 2020
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trialRobert J Motzer, Paul B Robbins, Thomas Powles, et al.Pageof 45